《大行報告》富瑞下調華虹半導體(01347.HK)目標價至55.2元 評級「買入」
華虹半導體(01347.HK)2021年全年純利2.12億美元,升113.3%;去年末季純利按年升92.9%至8,412.7萬美元。富瑞發表報告,表示華虹末季業績勝預期,管理層預期平均售價進一步提高,其仍然是中國半導體生產本地化和行業上升週期延長的受惠者。該行維持其「買入」評級,目標價由56.28元下調至55.2元。
富瑞表示,華虹幾乎所有產品主要使用平臺的需求均強勁,半導體生產本地化仍是一大投資主題,其12寸晶圓產能如期擴張。該行下調華虹對12寸晶圓毛利率預測,以反映在2022或2023年需要建造新晶圓廠。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.